A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Sotatercept (Primary) ; Ruxolitinib
- Indications Anaemia; Myelofibrosis
- Focus Therapeutic Use
- 16 Jun 2022 Status changed from active, no longer recruiting to completed.
- 14 Dec 2021 Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 02 Dec 2021 Status changed from recruiting to active, no longer recruiting.